Tuberculosis after one year of combination antiretroviral therapy in Nigeria: a retrospective cohort study.

Our objective was to determine tuberculosis (TB) incidence and evaluate TB risk in adults after one or more years of use of combination antiretroviral therapy (cART) through a retrospective cohort study in Jos, Nigeria. We studied a cohort of HIV-infected adults treated with ART for at least 1 year. Based on immunologic and virologic responses to ART, patients were categorized into four groups: CD4 T cell count ≥350 cells/mm(3) and HIV-1 RNA level ≤400 copies/ml (group 1), CD4 T cell count ≥350 cells/mm(3) and HIV-1 RNA level >400 copies/ml (group 2), CD4 T cell count <350 cells/mm(3) and HIV-1 RNA level ≤400 copies/ml (group 3), and CD4 T cell count <350 cells/mm(3) and HIV-1 RNA level >400 copies/ml (group 4). Time to incident TB for the four groups was analyzed using the Kaplan-Meier method. Cox regression models were used to evaluate predictors of incident TB. In this cohort of 5,093 HIV-infected adults, of which 68.4% were female, with a mean age 35.1 years (standard deviation 9.1 years), we observed 98 cases of incident TB during 4 years and 3 months of follow-up. The overall TB incidence rate was 8.7 cases/1,000 patient-years of follow-up. Adjusted hazards for incident TB were 2.11 (95% CI 0.97-4.61), 2.05 (95% CI 1.10-3.79), and 3.65 (95% CI 1.15-5.06) in group 2, 3, and 4 patients, respectively, compared to group 1. Tuberculosis incidence in patients on ART is driven by poor immunologic and/or virologic response. Optimization of HIV treatment should be prioritized to reduce the burden of TB in this high-risk population.

[1]  M. Diomande,et al.  Contribution of tuberculosis to slim disease in Africa , 1994, BMJ.

[2]  S. Lawn,et al.  Tuberculosis Incidence Rates during 8 Years of Follow-Up of an Antiretroviral Treatment Cohort in South Africa: Comparison with Rates in the Community , 2012, PloS one.

[3]  T. F. Rinke de Wit,et al.  Unnecessary Antiretroviral Treatment Switches and Accumulation of HIV Resistance Mutations; Two Arguments for Viral Load Monitoring in Africa , 2011, Journal of acquired immune deficiency syndromes.

[4]  T. Sterling,et al.  Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy. , 2009, The Journal of infectious diseases.

[5]  Christopher Dye,et al.  The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. , 2003, Archives of internal medicine.

[6]  R. Wood,et al.  Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study , 2002, The Lancet.

[7]  N. Nagelkerke,et al.  The Effect of Tuberculosis on Mortality in HIV Positive People: A Meta-Analysis , 2010, PloS one.

[8]  S. Lawn,et al.  Incidence of tuberculosis during highly active antiretroviral therapy in high-income and low-income countries. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  J. Sterne,et al.  Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  L. Ferradini,et al.  Tuberculosis after HAART initiation in HIV-positive patients from five countries with a high tuberculosis burden , 2006, AIDS.

[11]  S. Lawn,et al.  Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort , 2005, AIDS.

[12]  R. Adegbola,et al.  Investigation of the risk factors for tuberculosis: a case-control study in three countries in West Africa. , 2005, International journal of epidemiology.

[13]  B. Chi,et al.  Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in southern Africa , 2011, AIDS.

[14]  A. Date,et al.  Antiretroviral therapy and tuberculosis: what's the connection and what's the way forward? , 2011, Journal of acquired immune deficiency syndromes.

[15]  H. Whittle,et al.  Incidence of tuberculosis and survival after its diagnosis in patients infected with HIV-1 and HIV-2 , 2004, AIDS.

[16]  R. Crystal,et al.  Activation of alveolar macrophages in asymptomatic HIV-infected individuals. , 1993, Journal of immunology.

[17]  J. Sterne,et al.  Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries , 2006, The Lancet.

[18]  H. Twigg,et al.  Alveolar macrophages from HIV-infected subjects are resistant to Mycobacterium tuberculosis in vitro. , 2004, American journal of respiratory cell and molecular biology.

[19]  M. Molyneux,et al.  Mycobacterium tuberculosis Resides in Nonacidified Vacuoles in Endocytically Competent Alveolar Macrophages from Patients with Tuberculosis and HIV Infection1 , 2004, The Journal of Immunology.

[20]  J. Saukkonen,et al.  HIV impairs TNF-alpha mediated macrophage apoptotic response to Mycobacterium tuberculosis. , 2007, Journal of immunology.

[21]  Brian G. Williams,et al.  Antiretroviral Drugs for Tuberculosis Control in the Era of HIV/AIDS , 2003, Science.

[22]  R. Écochard,et al.  Short and Long-Term Incidence of Tuberculosis and CD4-Cell Count Dynamic on HAART in Senegal , 2009, The open AIDS journal.

[23]  R. Gie,et al.  Genetic susceptibility to tuberculosis in Africans: a genome-wide scan. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[24]  L. Myer,et al.  Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa , 2009, AIDS.

[25]  A. Kiragga,et al.  Incident Tuberculosis during Antiretroviral Therapy Contributes to Suboptimal Immune Reconstitution in a Large Urban HIV Clinic in Sub-Saharan Africa , 2010, PloS one.

[26]  L. Jeyaseelan,et al.  Post-HAART tuberculosis in adults and adolescents with HIV in India: incidence, clinical and immunological profile. , 2009, The Indian journal of tuberculosis.

[27]  E. Messou,et al.  Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan. , 2005, American journal of respiratory and critical care medicine.